Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes

被引：0
|
作者：
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Palo Alto VA Healthcare, Palo Alto, VA USA
来源：
LABORATORY INVESTIGATION | 2017年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
112
引用
收藏
页码：31A / 31A
页数：1
相关论文
共 50 条
  • [1] Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes
    Ballard, Morgan
    Troxell, Megan
    Jensen, Kristin
    Allison, Kimberly H.
    MODERN PATHOLOGY, 2017, 30 : 31A - 31A
  • [2] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
    Ballard, Morgan
    Troxell, Megan
    Jensen, Kristin
    Allison, Kimberly H.
    LABORATORY INVESTIGATION, 2017, 97 : 31A - 31A
  • [3] Breast Cancers with < 4 HER2 Signals/cell and Amplified HER2:CEP17 Ratios by FISH: Pathologic Features and Clinical Outcomes of Cases with "CEP17 Monosomy"
    Ballard, Morgan
    Troxell, Megan
    Jensen, Kristin
    Allison, Kimberly H.
    MODERN PATHOLOGY, 2017, 30 : 31A - 31A
  • [4] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals /cell >6.0 by FISH; A Multi-Institutional Study
    Ballard, Morgan
    Toukatly, Mirna
    Bean, Gregory
    Jalikis, Florencia
    Krings, Gregor
    Schmidt, Rodney
    Chen, Yunn-Yi
    Rendi, Mara
    Dintzis, Suzanne
    Troxell, Megan
    West, Robert
    Sibley, Richard
    Allison, Kimberly
    LABORATORY INVESTIGATION, 2018, 98 : 48 - 48
  • [5] Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals/cell >6.0 by FISH; A Multi-Institutional Study
    Ballard, Morgan
    Toukatly, Mirna
    Bean, Gregory
    Jalikis, Florencia
    Krings, Gregor
    Schmidt, Rodney
    Chen, Yunn-Yi
    Rendi, Mara
    Dintzis, Suzanne
    Troxell, Megan
    West, Robert
    Sibley, Richard
    Allison, Kimberly
    MODERN PATHOLOGY, 2018, 31 : 48 - 48
  • [6] Breast Carcinomas with Equivocal HER2/Neu Amplification: Morphologic Features, CEP17 Polysomy and HER2 Genetic Heterogeneity
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2012, 92 : 24A - 25A
  • [7] Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2:CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study
    Ballard, Morgan
    Toukatly, Mirna
    Bean, Gregory
    Jalikis, Florencia
    Krings, Gregor
    Schmidt, Rodney
    Chen, Yunn-Yi
    Dintzis, Suzanne
    Troxell, Megan
    West, Robert
    Sibley, Richard
    Allison, Kimberly
    LABORATORY INVESTIGATION, 2018, 98 : 47 - 48
  • [8] Pathologic Features and Clinical Outcomes of HER2 FISH Cases with HER2: CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional Study
    Ballard, Morgan
    Toukatly, Mirna
    Bean, Gregory
    Jalikis, Florencia
    Krings, Gregor
    Schmidt, Rodney
    Chen, Yunn-Yi
    Dintzis, Suzanne
    Troxell, Megan
    West, Robert
    Sibley, Richard
    Allison, Kimberly
    MODERN PATHOLOGY, 2018, 31 : 47 - 48
  • [9] Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry
    Davies, Vanessa
    Voutsadakis, Ioannis A.
    CANCER INVESTIGATION, 2020, 38 (02) : 94 - 101
  • [10] Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Daehne, Svenja
    Roma, Andres A.
    Hasteh, Farnaz
    Dell'Aquila, Marie
    Fadare, Oluwole
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2018, 42 (09) : 1208 - 1215
12345